Renalase, Stroke, and Hypertension in Hemodialyzed Patients

Małyszko, Jolanta; Koc-Żórawska, Ewa; Małyszko, J.; Kozminski, Piotr; Zbroch, Edyta; Myśliwiec, M

doi:10.3109/0886022x.2012.681534

Cited by 39 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 and 5, respectively. The results showed a significant difference in renalase level between CKD patients (stage 5) and CKD patients (stages 2-3), as shown in Table 4, which coincided with Gluba-Brzózka et al Cerqueira et al 2015 in their studies indicated that the renalase level in CKD patients (stage 5) was significantly higher than in CKD patients (stages 2-3), indicating that renalase level depends on the degree of renal function impairment and the rate of renal clearance of renalase, which depends on the eGFR [22,23]. One of these recent studies showed that the renalase level depends on the CKD stage, and there was a significant higher renalase level in CKD patients (stage 5) than in patients with CKD (stage 1-3) and strong negative correlation with eGFR [22], while Xu et al (2005) in their study concluded that the renalase plasma concentration is markedly reduced in patients with ESRD, as Al-Shamma compared with healthy subjects [6].…”

Section: Resultssupporting

confidence: 61%

The Possible Role of Renalase Enzyme in Cardiovascular Complications in Chronic Kidney Disease Patients

Al-Shamma

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The objective of this research was to study the possible role of renalase in the controlling blood pressure (BP) in patients with different stages of chronic kidney diseases (CKD) to decrease the incidents of cardiovascular disease in these patients. Methods:The serum levels of renalase were determined by enzyme-linked immune sorbent assay (ELISA) methods in 68 non-diabetic CKD patients in different stages (2-5). Fifty healthy control subjects were included in this study. Renalase high-sensitive C-reactive protein and Cystatin-C were measured by ELISA which is included first incubating the test serum in an antigen-coated polystyrene plate, then enzyme-labeled anti-immunoglobulin is added and the enzyme then remaining in plate after washing provides a measure of the amount of specific antibody in the serum, and in the final step, a substance is added that the enzyme can convert to some detectable signal, most commonly a color change in a chemical substrate.Results: There were a significant difference between serum levels of renalase, in CKD patients stage 5, and CKD patients 2-3 stage than in their healthy control group (p<0.05), in addition to a significant difference in renalase level between CKD stage, 2-3 and stage 5 (p<0.05). There was a significant positive correlation between serum renalase with systolic BP (p<0.05) in CKD patients stage 5. In addition, there was a significant negative correlation between the serum renalase and estimated glomerular filtration rate (p<0.05) in both groups. Conclusions:The main conclusion of the study was the positive significant correlation with systolic BP in CKD patients (stage 5). In addition, the serum renalase levels were elevated according the CKD stage in patients with CKD in different stages (2-5) and it increased with the deterioration of renal function.

show abstract

Section: Resultssupporting

confidence: 61%

The Possible Role of Renalase Enzyme in Cardiovascular Complications in Chronic Kidney Disease Patients

Al-Shamma

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Renalase has been proposed as a drug for replacement therapy in end stage renal disease [12,17,59,70,72], as early biomarker of acute kidney ischemia [10] and essential hypertension [8], as well as prognostic factor for stroke [27,45], and even as possible target for the therapy of psychiatric disorders caused by altered catecholaminergic signaling in the central nervous system [19]. Obviously, development of effective tools for pharmacological intervention requires the mechanism of renalase action to be known at the molecular level.…”

Section: Discussionmentioning

confidence: 99%

“…The same authors also investigated in chronic kidney disease patients the impact of hemodialysis and peritoneal dialysis 16 on blood serum renalase They concluded that impairment of renal function correlates with increased renalase levels [26][27][28], which was found up to 10-fold higher in anuric patients that underwent bilater nephrectomy in comparison to healthy subjects [26]. Finally, it was reported that stroke and hypertensions were associated to lower serum renalase concentrations in a hemodialysis population [27].…”

Section: Nadph-dependent Diaphorase Reactions With Various Artificialmentioning

confidence: 99%

“…A renalase concentration of 0.1 mg per gram wet tissue has been estimated in the kidneys by immunoblotting [10]. Data on the absolute concentration of renalase in human blood plasma have been explicitly reported only recently, as determined by ELISA, showing that it is about 4 g/ml in healthy individuals, corresponding to 0.1 M [23][24][25][26][27][28]. Murine renalase gene expression was observed by reverse transcriptase PCR in kidney, testicle, liver, heart, 12.5-days whole embryo, brain, and skeletal muscle [16].…”

Section: Renalase Isoforms and Gene Expression Patternmentioning

confidence: 99%

“…Finally, it was reported that stroke and hypertensions were associated to lower serum renalase concentrations in a hemodialysis population [27].…”

Section: Nadph-dependent Diaphorase Reactions With Various Artificialmentioning

confidence: 99%

See 2 more Smart Citations

Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme

Baroni¹,

Milani²,

Pandini³

et al. 2013

CPD

View full text Add to dashboard Cite

Renalase is a flavoprotein recently discovered in humans, preferentially expressed in the proximal tubules of the kidney and secreted in blood and urine. It is highly conserved in vertebrates, with homologs identified in eukaryotic and prokaryotic organisms. Several genetic, epidemiological, clinical and experimental studies show that renalase plays a role in the modulation of the functions of the cardiovascular system, being particularly active in decreasing the catecholaminergic tone, in lowering blood pressure and in exerting a protective action against myocardial ischemic damage. Deficient renalase synthesis might be the cause of the high occurrence of hypertension and adverse cardiac events in kidney disease patients. Very recently, recombinant human renalase has been structurally and functionally characterized in vitro. Results show that it belongs to the p-hydroxybenzoate hydroxylase structural family of flavoenzymes, contains non-covalently bound FAD with redox features suggestive of a dehydrogenase activity, and is not a catecholamine-degrading enzyme, either through oxidase or NAD(P)H-dependent monooxygenase reactions. The biochemical data now available will hopefully provide the basis for a systematic and rational quest toward the identification of the reaction catalyzed by renalase and of the molecular mechanism of its physiological action, which in turn are expected to favor the development of novel therapeutic tools for the treatment of kidney and cardiovascular diseases.

show abstract

Neurogenic Factors in Hypertension Associated With Chronic Kidney Disease

Campese¹

2014

Chronic Kidney Disease and Hypertension

View full text Add to dashboard Cite

Renalase, Stroke, and Hypertension in Hemodialyzed Patients

Cited by 39 publications

References 16 publications

The Possible Role of Renalase Enzyme in Cardiovascular Complications in Chronic Kidney Disease Patients

The Possible Role of Renalase Enzyme in Cardiovascular Complications in Chronic Kidney Disease Patients

Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme

Neurogenic Factors in Hypertension Associated With Chronic Kidney Disease

Contact Info

Product

Resources

About